Patents Assigned to Celularity, Inc.
  • Publication number: 20210032596
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: March 12, 2020
    Publication date: February 4, 2021
    Applicant: Celularity, Inc.
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20210002606
    Abstract: Provided herein are methods of culturing cells using microcarriers that include extracellular matrix (ECM).
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Applicant: Celularity Inc.
    Inventors: Robert J. HARIRI, Mohit BHATIA
  • Publication number: 20200397830
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Application
    Filed: January 24, 2020
    Publication date: December 24, 2020
    Applicant: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Publication number: 20200330516
    Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.
    Type: Application
    Filed: May 18, 2020
    Publication date: October 22, 2020
    Applicant: Celularity Inc.
    Inventors: Brian MURPHY, Vanessa VOSKINARIAN-BERSE, Andrea NORDBERG, Keith WILSON, Lin KANG
  • Publication number: 20200246385
    Abstract: Provided herein are micro-organoids, referred to herein as Functional Physiological Units (FPUs), that are capable of replacing or augmenting one or more physiological functions in an individual, which are useful in the treatment of individuals lacking, or suffering a deficit in, said physiological function.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Applicant: Celularity Inc.
    Inventors: Robert J. HARIRI, Mohit BHATIA, Jia-Lun WANG, Wolfgang HOFGARTNER, Qian YE
  • Publication number: 20200246393
    Abstract: Provided herein are methods of suppressing the growth or proliferation of tumor cells and methods of treating individuals having tumor cells using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer (PINK) cells, combined natural killer (NK) cells, or combinations thereof, in combination with an antibody (e.g., anti-disialoganglioside (anti-GD2) antibody). Also provided herein are compositions comprising placental perfusate, placental perfusate cells, PINK cells, combined NK cells, or combinations thereof, in combination with an antibody (e.g., anti-GD2 antibody).
    Type: Application
    Filed: September 27, 2018
    Publication date: August 6, 2020
    Applicant: CELULARITY, INC.
    Inventors: Xiaokui ZHANG, Lin KANG, Robert J. HARIRI
  • Publication number: 20200188446
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Application
    Filed: February 24, 2020
    Publication date: June 18, 2020
    Applicant: CELULARITY, INC.
    Inventor: Robert J. Hariri
  • Publication number: 20200138872
    Abstract: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.
    Type: Application
    Filed: December 16, 2019
    Publication date: May 7, 2020
    Applicant: CELULARITY, INC.
    Inventor: Naoko TAKEBE
  • Patent number: 10590381
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Celularity, Inc.
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 10564087
    Abstract: Provided are methods for quantifying and/or detecting sub-visible particulates in cell cultures. Specifically, the methods comprise a step of breaking down, e.g., lysing, cells in a cell culture. The methods can further comprising filtering the cell culture through a filter. Further provided are methods of quantifying sub-visible particulates that do not pass through the filter using a microscope.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: February 18, 2020
    Assignee: Celularity, Inc.
    Inventors: Lauren M. Depalma, Daniel Dewitt, Li Ren
  • Publication number: 20200048603
    Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
  • Patent number: 10548926
    Abstract: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: February 4, 2020
    Assignee: CELULARITY, INC.
    Inventor: Naoko Takebe
  • Publication number: 20200023015
    Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
    Type: Application
    Filed: August 5, 2019
    Publication date: January 23, 2020
    Applicant: CELULARITY, INC.
    Inventors: Uri Herzberg, Jodi P. Gurney
  • Publication number: 20200009199
    Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.
    Type: Application
    Filed: August 5, 2019
    Publication date: January 9, 2020
    Applicant: CELULARITY, INC.
    Inventor: Robert J. Hariri
  • Publication number: 20190388478
    Abstract: Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI).
    Type: Application
    Filed: August 14, 2019
    Publication date: December 26, 2019
    Applicant: CELULARITY, INC.
    Inventors: Steven A. Fischkoff, Hong-Jung Chen
  • Publication number: 20190376027
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 12, 2019
    Applicant: Celularity, Inc.
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 10494607
    Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: December 3, 2019
    Assignee: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
  • Publication number: 20190330592
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 31, 2019
    Applicant: Celularity, Inc.
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20190321413
    Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.
    Type: Application
    Filed: May 30, 2019
    Publication date: October 24, 2019
    Applicant: CELULARITY, INC.
    Inventors: Mohammad A. Heidaran, Robert J. Hariri, Kristine Erickson Johnson
  • Publication number: 20190314424
    Abstract: Provided herein are methods of using tissue culture plastic-adherent placental adherent cells, e.g. placental stem cells, referred to herein as placental adherent cells, to treat lymphedema and lymphedema-related disorders.
    Type: Application
    Filed: December 6, 2017
    Publication date: October 17, 2019
    Applicant: CELULARITY, INC.
    Inventors: Robert J. Hariri, Shuyang He